{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:45:18Z","timestamp":1792633518047,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied. Despite that, there is increasing use of advanced molecular diagnostics that identify potential targets, and tumor-agnostic regulatory approvals on targets also present in CNS tumors have been granted. This raises the question of when and for which targets it is meaningful to test in adult patients with CNS tumors. This evidence-based guideline reviews the evidence available for targeted treatment for alterations in the RAS\/MAPK pathway (BRAF, NF1), in growth factor receptors (EGFR, ALK, fibroblast growth factor receptor (FGFR), neurotrophic tyrosine receptor kinase (NTRK), platelet-derived growth factor receptor alpha, and ROS1), in cell cycle signaling (CDK4\/6, MDM2\/4, and TSC1\/2) and altered genomic stability (mismatch repair, POLE, high tumor mutational burden (TMB), homologous recombination deficiency) in adult patients with gliomas, glioneuronal and neuronal tumors. At present, targeted treatment for BRAF p.V600E alterations is to be considered part of the standard of care for patients with recurrent gliomas, pending regulatory approval. For approved tumor agnostic treatments for NTRK fusions and high TMB, the evidence for efficacy in adult patients with CNS tumors is very limited, and treatment should preferably be given within prospective clinical registries and trials. For targeted treatment of CNS tumors with FGFR fusions or mutations, clinical trials are ongoing to confirm modest activity so far observed in basket trials. For all other reviewed targets, evidence of benefit in CNS tumors is currently lacking, and testing\/treatment should be in the context of available clinical trials.<\/jats:p>","DOI":"10.1093\/neuonc\/noad008","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T03:56:34Z","timestamp":1673495794000},"page":"813-826","source":"Crossref","is-referenced-by-count":114,"title":["EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-497X","authenticated-orcid":false,"given":"David","family":"Capper","sequence":"first","affiliation":[{"name":"Department of Neuropathology, Charit\u00e9 \u2014 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ) , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Reifenberger","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology and German Cancer Consortium (DKTK), Partner Site Essen\/D\u00fcsseldorf, Heinrich Heine University, Medical Faculty University Hospital D\u00fcsseldorf , Moorenstrasse 5, D-40225 D\u00fcsseldorf , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J","family":"French","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-2587","authenticated-orcid":false,"given":"Leonille","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Institute of Neurology (Edinger Institute), University Hospital Frankfurt, Goethe University , Frankfurt am Main , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Frankfurt\/Mainz, German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Frankfurt Cancer Institute (FCI) , Frankfurt am Main , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, Service de Neurologie 2-Mazarin , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-9534","authenticated-orcid":false,"given":"Simone P","family":"Niclou","sequence":"additional","affiliation":[{"name":"Department of Cancer Research, NORLUX Neuro-Oncology Laboratory, Luxembourg Institute of Health , 6A, rue Nicolas Ernest-Barbl\u00e9 , L-1210 Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9138-805X","authenticated-orcid":false,"given":"Philipp","family":"Euskirchen","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Charit\u00e9 \u2014 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin , Germany"},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Klinik f\u00fcr Neurologie, Charit\u00e9platz 1, 10117 Berlin , Germany"},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Charit\u00e9 Comprehensive Cancer Center , Charit\u00e9platz 1, 10117 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1016-0545","authenticated-orcid":false,"given":"Christine","family":"Haberler","sequence":"additional","affiliation":[{"name":"Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika E","family":"Hegi","sequence":"additional","affiliation":[{"name":"Neuroscience Research Center, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-0342","authenticated-orcid":false,"given":"Sebastian","family":"Brandner","sequence":"additional","affiliation":[{"name":"Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London London , UK"},{"name":"Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[{"name":"Division of Neurology, Castelfranco Veneto\/Treviso Hospital"},{"name":"Division of Neuro-Oncology, Department of Neuroscience, University of Turin , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sanson","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, Service de Neurologie 2-Mazarin , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-8782","authenticated-orcid":false,"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital T\u00fcbingen and Hertie Institute for Clinical Brain Research, Eberhard Karls University T\u00fcbingen"},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen"},{"name":"German Cancer Consortium (DKTK), partner site T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital Heidelberg, CCU Neuropathology , Heidelberg , Germany"},{"name":"German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center For Neuro-Oncology, Dana-Farber Cancer institute and Harvard Medical School , Boston , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Wesseling","sequence":"additional","affiliation":[{"name":"Department of Pathology, Amsterdam University Medical Centers\/VUmc ( De Boelelaan 1117, 1081 HV) Amsterdam , The Netherlands"},{"name":"Laboratory for Childhood Cancer Pathology, Princess M\u00e1xima Center for Pediatric Oncology (Heidelberglaan 25 , 3584 CS Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin J","family":"van den Bent","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"2023050411180708000_CIT0001","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"9","key":"2023050411180708000_CIT0002","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol."},{"issue":"1","key":"2023050411180708000_CIT0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol."},{"key":"2023050411180708000_CIT0004","first-page":"209","article-title":"FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma","volume":"8","author":"Schittenhelm","year":"2021","journal-title":"Neurooncol Pract."},{"key":"2023050411180708000_CIT0005","first-page":"14932","article-title":"C-MET overexpression and amplification in gliomas","volume":"8","author":"Kwak","year":"2015","journal-title":"Int J Clin Exp Pathol."},{"issue":"2","key":"2023050411180708000_CIT0006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/08830738040190020401","article-title":"Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis","volume":"19","author":"J\u00f3\u017awiak","year":"2004","journal-title":"J Child Neurol."},{"issue":"4","key":"2023050411180708000_CIT0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00401-014-1246-6","article-title":"Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms","volume":"127","author":"Reuss","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"7804","key":"2023050411180708000_CIT0008","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature."},{"issue":"2","key":"2023050411180708000_CIT0009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00401-018-1879-y","article-title":"Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience","volume":"136","author":"Capper","year":"2018","journal-title":"Acta Neuropathol."},{"key":"2023050411180708000_CIT0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"issue":"12","key":"2023050411180708000_CIT0011","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project","volume":"32","author":"Vega","year":"2021","journal-title":"Ann Oncol."},{"key":"2023050411180708000_CIT0012","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med."},{"key":"2023050411180708000_CIT0013","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J ImmunoTher Cancer."},{"key":"2023050411180708000_CIT0014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jmedgenet-2014-102284","article-title":"Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium \u201ccare for CMMRD\u201d (C4CMMRD)","volume":"51","author":"Wimmer","year":"2014","journal-title":"J Med Genet."},{"issue":"5","key":"2023050411180708000_CIT0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ejca.2013.12.005","article-title":"Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium","volume":"50","author":"Bakry","year":"2014","journal-title":"Eur J Cancer."},{"key":"2023050411180708000_CIT0016","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/jmedgenet-2020-107627","article-title":"Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group","volume":"59","author":"Aronson","year":"2022","journal-title":"J Med Genet."},{"issue":"6","key":"2023050411180708000_CIT0017","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat."},{"key":"2023050411180708000_CIT0018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn."},{"key":"2023050411180708000_CIT0019","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med."},{"issue":"5","key":"2023050411180708000_CIT0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"issue":"9","key":"2023050411180708000_CIT0021","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol."},{"issue":"11","key":"2023050411180708000_CIT0022","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/ijc.32358","article-title":"Variant classification in precision oncology","volume":"145","author":"Leichsenring","year":"2019","journal-title":"Int J Cancer."},{"issue":"26","key":"2023050411180708000_CIT0023","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med."},{"key":"2023050411180708000_CIT0024","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-022-00117-y","article-title":"BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov."},{"key":"2023050411180708000_CIT0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113246","article-title":"Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: an intra-patient comparative analysis","volume":"12","author":"Italiano","year":"2020","journal-title":"Cancers."},{"key":"2023050411180708000_CIT0026","author":"(CHMP) EMACfMPfHU","year":"2017"},{"key":"2023050411180708000_CIT0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7150\/jca.3.7","article-title":"Progression-free survival decreases with each subsequent therapy in patients presenting for phase I clinical trials","volume":"3","author":"Bailey","year":"2012","journal-title":"J Cancer."},{"issue":"33","key":"2023050411180708000_CIT0028","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol."},{"key":"2023050411180708000_CIT0029","article-title":"Ivosidenib in isocitrate dehydrogenase 1\u2013mutated advanced glioma","author":"Mellinghoff","journal-title":"J Clin Oncol."},{"issue":"10","key":"2023050411180708000_CIT0030","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol."},{"issue":"7785","key":"2023050411180708000_CIT0031","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature."},{"key":"2023050411180708000_CIT0032","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J Clin Oncol."},{"issue":"3","key":"2023050411180708000_CIT0033","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/neup.12459","article-title":"Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma","volume":"38","author":"Furuta","year":"2018","journal-title":"Neuropathology."},{"key":"2023050411180708000_CIT0034","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00401-019-02002-2","article-title":"An update on the central nervous system manifestations of neurofibromatosis type 1","volume":"139","author":"Nix","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2023050411180708000_CIT0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11060-019-03258-0","article-title":"Tumor pharmacokinetics and pharmacodynamics of the CDK4\/6 inhibitor ribociclib in patients with recurrent glioblastoma","volume":"144","author":"Miller","year":"2019","journal-title":"J Neurooncol."},{"issue":"19","key":"2023050411180708000_CIT0036","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","article-title":"A phase 0 trial of ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic- and pharmacokinetic-guided expansion cohort","volume":"25","author":"Tien","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2023050411180708000_CIT0037","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","article-title":"Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma","volume":"140","author":"Taylor","year":"2018","journal-title":"J Neurooncol."},{"issue":"6","key":"2023050411180708000_CIT0038","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00401-020-02226-7","article-title":"Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology","volume":"140","author":"Golebiewska","year":"2020","journal-title":"Acta Neuropathol."},{"key":"2023050411180708000_CIT0039","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00401-020-02243-6","article-title":"Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis","volume":"141","author":"Suwala","year":"2021","journal-title":"Acta Neuropathol."},{"key":"2023050411180708000_CIT0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noad008\/49603287\/noad008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/5\/813\/50196297\/noad008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/5\/813\/50196297\/noad008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T08:37:36Z","timestamp":1683189456000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/5\/813\/6985907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,12]]},"published-print":{"date-parts":[[2023,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noad008","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,1,12]]}}}